You are here: Industry Insights > alzheimer

News List

Alzheimer’s - Hypotheses & Drug Targets David Orchard-Webb
July 31, 2023
The blood-brain barrier (BBB) is a physical barrier that keeps the extracellular fluid of the brain separate from the bloodstream.
Alzheimer’s Disease - Recent Advances in Treatment Neeta Ratanghayra
August 06, 2021
Alzheimer's disease (AD) is a neurodegenerative disease affecting millions of people globally.
ADUHELM: The First FDA Approved Therapy for Alzheimer’s Disease Since 2003 Lin Zhang
July 20, 2021
Aducanumab, known as ADUHELM, was co-developed by Biogen and Eisai and newly approved by the United States Food and Drug Administration (FDA) on June 7, 2021 (BLA 761178) under the provisions of accelerated approval regulations (21 CFR 601.41).
Biogen urges Medicare to reverse proposed limits on coverage of Alzheimer's drug FirstWordPharma
February 11, 2022
Biogen is urging Medicare to broadly reimburse its Alzheimer's drug Aduhelnm, in response to a proposal by the US Centers for Medicaid and Medicare Services (CMS) to sharply limit coverage of new drugs for the disease...
Medicare May Rethink Premium Hike for Pricey Alzheimer Drug drugs
January 10, 2022
Medicare has been told to reassess a significant premium increase it had announced that largely stemmed from the expensive new Alzheimer disease drug Aduhelm.
Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation Drugs
December 29, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today...
FDA grants fast track designation to Eisai-Biogen’s Alzheimer’s therapy Pharmaceutical-Technology
December 27, 2021
The US Food and Drug Administration (FDA) has granted Fast Track designation to Eisai and Biogen’s experimental drug, lecanemab, to treat early Alzheimer’s disease (AD).
University of Glasgow reveals drug design for new Alzheimer’s treatments PharmaTimes
December 01, 2021
A team of scientists and pharmaceutical collaborators have discovered a ‘bench to bedside’ drug design, which will hopefully improve the future treatment of Alzheimer’s disease...
NIH study says repurposed cancer therapies beneficial for Alzheimer’s Pharmaceutical-Technology
November 12, 2021
Scientists from the US National Institutes of Health (NIH) unit National Institute on Aging (NIA) have found that present and developing therapies for cancer could potentially...
Luye Pharma Grants Zambon Exclusive Commercialization Rights to Its Innovative Alzheimer's Disease Treatment Rivastigmine Multi-Day Transdermal Patch in Switzerland prnasia
November 11, 2021
Luye Pharma Group (Luye Pharma) today announced that its subsidiary Luye Pharma Switzerland AG has entered into an agreement with Zambon Switzerland (Zambon)...